At the 2025 Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Diego, Dr Joanne Pike, President and CEO of the Alzheimer’s Association and Chair of the World Dementia Council, will host a working lunch focused on advancing public policy to drive innovation. 

Innovation is the engine of progress in dementia research, driving breakthroughs in treatment, diagnosis and prevention. As the field enters a new era marked by disease-modifying therapies, rapid advances in biomarkers, AI, and precision medicine are reshaping what is possible. This session will explore how public policy must evolve to support this momentum — creating an ecosystem that fosters collaboration, encourages risk-taking, and integrates scientific, regulatory, and commercial efforts to accelerate impact.

The lunch, inviation only, is part of a series of events the Council is hosting exploring innovation in dementia. 

  • Biomarkers: Lessons from Innovators

    Chaired by Dr Howard Fillit, Chief Science Officer Alzheimer's Drug Discovery Fund and Dr Stacie Weninger President of FBRI, this virtual dialogue will explore the different experiences, and the lessons from that, of companies and funders innovating in the biomarker field. With opening remarks from Randall Bateman, Charlotte Teunissen, Michael Weiner and Henrik Zetterberg followed by a roundtable discussion for all participants in the dialogue.

    Read more